Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Acral, Mucosal, or Chronic Sun-damaged Melanoma
NCT01092728Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2011
- Primary completion
- Aug 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in acral lentiginous melanoma (ALM), mucosal melanoma (MM) and melanoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Biologic Response Evaluation of Tumors at Day 35. Started Mar 2011; status: terminated.
02
Drugs
dasatinib
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)melanoma
Beyond the preview
Go deeper on NCT01092728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01092728.